Clinical Research Directory

Inclusion Criteria: * The investigator thinks that the subject can continue to benefit from participating in the extension trial; * Fully understand the extension trial and sign the informed consent form; * Complete the ZGJAK025 trial for 16 weeks and have good compliance; * It is expected that the time interval between the first administration and the last administration of ZGJAK025 trial for the subject should be ≤ 4 weeks; Exclusion Criteria: * Within 4 weeks before enrollment, there were any adverse events ≥ 3 levels related to the test drug that did not return to level 1 or normal; * The investigator thinks that the subject is not suitable for the trial.